Biological ageing and frailty markers in breast cancer patients.
Biological ageing and frailty markers in breast cancer patients.
复制标题
DOI：
10.18632/aging.100745
复制
发表时间：
2015-05
期刊：
影响因子：
--
通讯作者：
Wildiers H
中科院分区：
文献类型：
--
作者：
Brouwers B;Dalmasso B;Hatse S;Laenen A;Kenis C;Swerts E;Neven P;Smeets A;Schöffski P;Wildiers H
就整体健康状况和生理储备而言，老年癌症患者是一个高度异质的人群，通常很难确定最佳治疗方法。此外，目前用于评估全球健康的临床工具需要专门的时间，并且缺乏标准化的最终评分。生物年龄和/或健康的循环标记可以补充或部分替代现有的筛查工具。在这项研究中，我们探讨了潜在的衰老/衰弱生物标志物与年龄和临床衰弱的关系。在 82 名年轻非转移性乳腺癌患者和 162 名老年非转移性乳腺癌患者中，我们测量了平均白细胞端粒长度和血浆白细胞介素 6 (IL-6)、激活后调节的白细胞介素 6 (IL-6)、正常 T 细胞表达和分泌 (RANTES)、单核细胞趋化蛋白 1 (MCP-1)、胰岛素样生长因子 1 (IGF-1) 的水平。我们还开发了一种新工具来总结临床虚弱，将 GA 结果整合到单个半连续评分中，称为鲁汶肿瘤老年虚弱评分 (LOFS)。 LOFS 的中位分数为 8，评分范围为 0=虚弱到 10=健康。 IL-6 水平与两组的实际年龄以及老年乳腺癌患者的临床虚弱程度相关，而端粒长度、IGF-1 和 MCP-1 仅与年龄相关。应进一步探索血浆 IL-6 作为癌症患者虚弱的生物标志物。
Older cancer patients are a highly heterogeneous population in terms of global health and physiological reserves, and it is often difficult to determine the best treatment. Moreover, clinical tools currently used to assess global health require dedicated time and lack a standardized end score. Circulating markers of biological age and/or fitness could complement or partially substitute the existing screening tools. In this study we explored the relationship of potential ageing/frailty biomarkers with age and clinical frailty. On a population of 82 young and 162 older non-metastatic breast cancer patients, we measured mean leukocyte telomere length and plasma levels of interleukin-6 (IL-6), regulated upon activation, normal T cell expressed and secreted (RANTES), monocyte chemotactic protein 1 (MCP-1), insulin-like growth factor 1 (IGF-1). We also developed a new tool to summarize clinical frailty, designated Leuven Oncogeriatric Frailty Score (LOFS), by integrating GA results in a single, semi-continuous score. LOFS' median score was 8, on a scale from 0=frail to 10=fit. IL-6 levels were associated with chronological age in both groups and with clinical frailty in older breast cancer patients, whereas telomere length, IGF-1 and MCP-1 only correlated with age. Plasma IL-6 should be further explored as frailty biomarker in cancer patients.